Saturday, 3 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· February 10, 2026

LHV Groupi 2025. aasta IV kvartali ja 12 kuu auditeerimata majandustulemused

View original at globenewswire.com
LHV Groupi 2025. aasta IV kvartali ja 12 kuu auditeerimata majandustulemused 2025. aasta lõpus näitasid LHV Groupi deposiitide kui ka laenuportfelli mahud väga tugevat kasvu…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Although annual profit fell short of financial plan by 6.5%, Q4 was strong with nearly 9,000 new clients added in Estonia and strong growth in both deposits and loan portfolios

    80% confidence

  • LHV Kindlustus doubled its profit

    80% confidence

  • Moody's ratings confirm LHV's strong financial position and capitalization and express expectation for credit quality strengthening

    80% confidence

  • LHV Varahaldus offered market-best returns and significantly exceeded financial plan

    80% confidence

  • LHV Group is confident that 2025 year-end capital adequacy is calculated correctly and in compliance with regulatory requirements

    80% confidence

  • LHV Bank UK showed particularly fast growth with loan portfolio doubling over the year and retail client count reaching 5,000 by year-end

    80% confidence

  • Despite challenging interest rate environment in first half of year, LHV finished 2025 with strong fourth quarter with interest income returning to growth and significant increase in fee income from high client activity

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com